23andMe Is Really a Biotech Firm, Analyst Says - Barrons
23andMe Company Profile: Stock Performance & Earnings | PitchBook
GSK invests $20 million in 23andMe for DNA data access and analysis By Investing.com
Direct-to-Consumer Genetic Testing Market Size to Grow by USD 1.38 billion | 23andMe Inc. and Alpha Biolaboratories Ltd. Among Key Vendors | Technavio
Case study on 23andMe. Get these analyses to your inbox —… | by Axial | Medium
Institutional owners may consider drastic measures as 23andMe Holding Co.'s (NASDAQ:ME) recent US$85m drop adds to long-term losses - Simply Wall St News
ME - 23andMe Holding Co - Class A Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)
23andMe (ME) Stock Price, News & Info | The Motley Fool
DNA Test Kits Market to reach US$ 2.7 bn by 2030
23andMe Holding Co. (ME) Stock Price, Quote & News - Stock Analysis
Case study on 23andMe. Get these analyses to your inbox —… | by Axial | Medium
23andMe Stock: Weak Results Could Mean Potential Acquisition Target | Seeking Alpha
23andMe Is Terrifying, but Not for the Reasons the FDA Thinks - Scientific American
23andMe: Treacherous Path To Profitability (NASDAQ:ME) | Seeking Alpha
23andMe Holding Co. Class A Common Stock (ME) Stock Price, Quote, News & History | Nasdaq
Genealogical Database Growth Slows – The DNA Geek
23andMe: Still On The Sidelines (NASDAQ:ME) | Seeking Alpha
23andMe: Treacherous Path To Profitability (NASDAQ:ME) | Seeking Alpha
23andMe (ME) - Market capitalization
Anne Wojcicki's 23andMe Fortune Falls Under $1 Billion As Shares Sink Post-IPO
Direct-To-Consumer Genetic Testing Market Size, Report 2032
